Form 4: Athira Pharma's Chief Scientific Officer Reports Stock Transactions

Kevin Church, Chief Scientific Officer of Athira Pharma, reports stock acquisitions and disposals, including ESPP purchases and sales to cover tax obligations.

Summary

• Kevin Church, the Chief Scientific Officer of Athira Pharma, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On November 18, 2024, Church acquired 9,920 shares of common stock through the Employee Stock Purchase Plan (ESPP) at a price of $0.55 per share.
• On December 31, 2024, 36,667 shares were acquired through the vesting of Restricted Stock Units (RSUs).
• On January 2, 2025, 8,510 shares were sold at an average price of $0.5619 to cover tax obligations related to the RSU vesting.
• Following these transactions, Church directly owns 130,761 shares of Athira Pharma common stock and 73,333 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to employee compensation and does not indicate any significant positive or negative developments.

Positives

• The acquisition of shares through the ESPP demonstrates the reporting person's investment in the company's future.

Negatives

• The sale of shares to cover tax obligations, while routine, slightly reduces the reporting person's holdings.

Future Outlook

The reporting person will continue to vest in RSUs on June 30, 2025, and December 31, 2025, subject to continued service.

Industry Context

Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their transactions in the company's stock. This filing indicates the Chief Scientific Officer's ongoing investment in the company through participation in the ESPP and RSU grants.

Comparison to Industry Standards

• Insider transactions are common across the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also have executives who regularly report stock transactions via Form 4 filings.
• The ESPP participation is a standard benefit offered by many companies to encourage employee ownership.
• The 'sell to cover' practice for RSU vesting is also a common method to manage tax obligations.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine insider activity.
• Employees participating in the ESPP benefit from the opportunity to purchase company stock at a discounted rate.

Next Steps

• Continued vesting of RSUs on June 30, 2025, and December 31, 2025.

Key Dates